Fate Therapeutics, Inc.
FATE
$0.9578
-$0.2122-18.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.98% | 58.13% | 625.83% | -96.74% | -96.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.98% | 58.13% | 625.83% | -96.74% | -96.22% |
| Cost of Revenue | 4.46% | 1.09% | -15.34% | -51.03% | -81.18% |
| Gross Profit | -3.72% | 2.34% | 30.32% | -354.40% | 65.61% |
| SG&A Expenses | -4.83% | 9.78% | -23.74% | -4.96% | 54.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.77% | 4.19% | -18.34% | -39.49% | -54.26% |
| Operating Income | 2.21% | -2.14% | 27.94% | -78.61% | 25.37% |
| Income Before Tax | -18.20% | -5.55% | 27.16% | -154.25% | 21.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.20% | -5.55% | 27.16% | -154.25% | 21.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.20% | -5.55% | 27.16% | -154.25% | 21.72% |
| EBIT | 2.21% | -2.14% | 27.94% | -78.61% | 25.37% |
| EBITDA | 2.30% | -2.65% | 30.53% | -89.53% | 27.51% |
| EPS Basic | 1.05% | 11.67% | 38.99% | -146.52% | 22.82% |
| Normalized Basic EPS | 36.38% | 11.66% | 44.06% | -146.63% | 13.88% |
| EPS Diluted | 1.05% | 11.67% | 38.99% | -146.52% | 22.89% |
| Normalized Diluted EPS | 36.38% | 11.66% | 44.06% | -146.63% | 13.88% |
| Average Basic Shares Outstanding | 19.45% | 19.48% | 19.38% | 3.11% | 1.43% |
| Average Diluted Shares Outstanding | 19.45% | 19.48% | 19.38% | 3.11% | 1.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |